Mechanisms of Altered Bone Remodeling in Multiple Myeloma

被引:1
|
作者
Brunetti G. [1 ]
Faienza M.F. [2 ]
Colaianni G. [1 ]
Grano M. [3 ]
Colucci S. [1 ]
机构
[1] Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Human Anatomy and Histology, University “Aldo Moro” of Bari, Piazza Giulio Cesare, 11, Bari
[2] Department of Biomedical Sciences and Human Oncology, Pediatric Section, University “A. Moro” of Bari, Bari
[3] Department of Emergency and Organ Transplantation, Section of Human Anatomy and Histology, University “A. Moro” of Bari, Bari
来源
关键词
LIGHT; Multiple myeloma; Osteoblasts; Osteoclasts; RANKL; Wnt signaling;
D O I
10.1007/s12018-017-9236-6
中图分类号
学科分类号
摘要
Multiple myeloma (MM) is a hematologic malignancy of plasma cells proliferating in the bone marrow and it is associated with the osteolytic bone disease. About 70% of myeloma patients show the bone disease at diagnosis and 15–20% have pathologic fractures. The osteolytic disease is due to the altered bone remodeling with increased activity of osteoclasts, the bone resorbing cells, and the reduced activity of osteoblasts, the bone forming cells. In the bone marrow microenvironment, the deregulated activity of bone cells is due to the malignant plasma cells through the release of soluble molecules or cell-cell contact. Recently, the key role of osteocytes, the orchestrators of bone remodeling, and the adipocytes has been highlighted in MM-bone disease. In this review, we overview the mechanisms leading to increased bone resorption as well as suppressed osteoblast formation and activity in MM-bone disease, thus highlighting cytokines that will represent new therapeutic targets to improve bone health in MM-bone disease. © 2017, Springer Science+Business Media, LLC.
引用
收藏
页码:151 / 161
页数:10
相关论文
共 50 条
  • [21] Systemic bone remodeling in multiple myeloma, smoldering myeloma, and healthy subjects: Global assessment with NaF-PET
    Raynor, William
    Zadeh, Mahdi Zirakchian
    Acosta-Montenegro, Oswaldo
    Al-Zaghal, Abdullah
    Yellanki, Dani
    Oestergaard, Brian
    Werner, Thomas
    Zhuang, Hongming
    Abildgaard, Niels
    Hoilund-Carlsen, Poul Flemming
    Alavi, Abass
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [22] Cellular mechanisms of bone remodeling
    Eriksen, Erik Fink
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2010, 11 (04): : 219 - 227
  • [23] Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    Breitkreutz, I.
    Raab, M. S.
    Vallet, S.
    Hideshima, T.
    Raje, N.
    Mitsiades, C.
    Chauhan, D.
    Okawa, Y.
    Munshi, N. C.
    Richardson, P. G.
    Anderson, K. C.
    LEUKEMIA, 2008, 22 (10) : 1925 - 1932
  • [24] Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    I Breitkreutz
    M S Raab
    S Vallet
    T Hideshima
    N Raje
    C Mitsiades
    D Chauhan
    Y Okawa
    N C Munshi
    P G Richardson
    K C Anderson
    Leukemia, 2008, 22 : 1925 - 1932
  • [25] Cellular mechanisms of bone remodeling
    Erik Fink Eriksen
    Reviews in Endocrine and Metabolic Disorders, 2010, 11 : 219 - 227
  • [26] Mechanisms of bone destruction in myeloma
    Roodman, GD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P12 - P12
  • [27] Altered Expression of MicroRNAs in the Bone Marrow of Multiple Myeloma Patients and their Relationship to Cytogenetic Aberrations
    Attia, Hanaa R. M.
    Abdelrahman, Amany H.
    Ibrahim, Mona H.
    Eid, Maha M.
    Eid, Ola M.
    Sallam, Mohamed T.
    El Gammal, Mosaad M.
    Kamel, Mahmoud M.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2020, 21 (13) : 1394 - 1401
  • [28] Increased osteoprotegerin levels in response to increased bone resorption in AL amyloiaosis: Comparisons with bone remodeling of multiple myeloma
    Kastritis, E.
    Dimopoulos, Meletios Athanasios
    Mihail, M.
    Mihali, E.
    Kyrtsonis, M. C.
    Detimpassi, S.
    Katodritou, E.
    Anagnostopoulos, N.
    Kokkini, G.
    Zervas, K.
    Anargyrou, K.
    Panagicitidis, P.
    Terpos, E.
    BLOOD, 2007, 110 (11) : 1033A - 1033A
  • [29] Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease
    Adamik, Juraj
    Roodman, G. David
    Galson, Deborah L.
    JBMR PLUS, 2019, 3 (03)
  • [30] Immunoregulatory mechanisms in multiple myeloma
    Munshi, NC
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) : 51 - &